about
From selection hits to clinical leads: progress in aptamer discoveryAflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degenerationTreatment of Exudative Age-related Macular Degeneration: Focus on AfliberceptComparative safety and tolerability of anti-VEGF therapy in age-related macular degenerationA review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methodsMaculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: A case report.O-glycosylation of glycine-serine linkers in recombinant Fc-fusion proteins: attachment of glycosaminoglycans and other intermediates with phosphorylation at the xylose sugar subunit.The mechanism of CCN1-enhanced retinal neovascularization in oxygen-induced retinopathy through PI3K/Akt-VEGF signaling pathway.Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eyeClinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration.Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration.Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.Advances in pharmacotherapy for wet age-related macular degeneration.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.The role of Aflibercept in the management of age-related macular degeneration.Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot studyNon-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment.Ocular delivery of proteins and peptides: challenges and novel formulation approaches.Tanshinone IIA Inhibits VEGF Secretion and HIF-1α Expression in Cultured Human Retinal Pigment Epithelial Cells under Hypoxia.Effects of intravitreal aflibercept and ranibizumab on retinal vessel diameter measured using fluorescein angiography.Hyperhomocysteinemia Causes Chorioretinal Angiogenesis with Placental Growth Factor UpregulationAptamers as Diagnostic Tools in Cancer
P2860
Q26752799-4ECF866A-C8A2-4CDD-987D-3533F539007EQ26771522-0D58A28B-773B-4EFA-AF1F-F70E07FBE6DCQ26786766-EC10E31A-F806-4B0C-8D39-A8F16F495549Q26852289-415CDEDD-9FE8-4B5E-8583-B5D5081503EFQ26998969-70243DE2-ADFB-4683-B141-EEA7DD915081Q33760560-D1F2554B-E585-4A7A-BEC5-C74B59FA1284Q34223974-B060F715-527B-444A-A928-6487BCC7C992Q35586224-71A73A91-19F1-48DB-A7BD-5C31A2E0885AQ35754989-1BA3844B-A1A5-4BDA-81CB-F50B47CF6F04Q35892420-8264C69F-643D-4EC2-BC21-CA8F4B512F7AQ37361488-27125CC5-EFAF-425A-8DAA-8002AA4000EEQ37729097-D99693AB-124C-4B21-BD32-43ABCD7E4D81Q38210239-D7A568D0-87D1-4F9C-8321-424E071E82BDQ38528148-6EA7291E-5AAA-4A78-8826-6B4B45E3A0C9Q38545575-702AEEAB-6CAF-4713-AAA7-D7D3AB46B591Q38633532-4C5FA5B3-004B-425F-875D-A9ACF322834CQ38777050-B5BF5FC6-A3F6-45F9-94A0-88FB53CC50B6Q42339139-F3F6480E-F5CB-4857-BE08-9EB3C8D917E7Q42426609-0612E961-66B7-422B-8644-94599B8D97FAQ47729137-E324F03A-4ABF-49B9-9F28-D24D5AEEE065Q47765595-950EDD7D-7A0F-437E-B828-C050B5114DD1Q48129913-9049C388-24BB-47FD-BCE9-EB4FB4B864D8Q58562948-D509C31B-3F6D-4E41-893C-C514171FCB19Q58749805-5FC48B48-D452-445E-9D15-7D996CEBCA16
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aflibercept in wet AMD: specific role and optimal use.
@en
Aflibercept in wet AMD: specific role and optimal use.
@nl
type
label
Aflibercept in wet AMD: specific role and optimal use.
@en
Aflibercept in wet AMD: specific role and optimal use.
@nl
prefLabel
Aflibercept in wet AMD: specific role and optimal use.
@en
Aflibercept in wet AMD: specific role and optimal use.
@nl
P2093
P2860
P921
P356
P1476
Aflibercept in wet AMD: specific role and optimal use
@en
P2093
E Gambicorti
F Morescalchi
F Parmeggiani
P2860
P304
P356
10.2147/DDDT.S40215
P407
P5008
P577
2013-08-05T00:00:00Z